This is a routine Form 144 filing by a director following a consistent monthly sale pattern. No material signal for the stock. Monitor for any acceleration in insider selling volume or unexpected C-suite filings, but this filing alone warrants no action.
MIRM drugs
MIRM drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 2 $92.17entry
- T+1 · 6mo ago −0.36%α +0.33% · $91.84
- T+5 · 5mo ago +3.59%α +6.56% · $95.48
- T+20 · 5mo ago +30.69%α +32.26% · $120.46
- T+60 · 3mo ago +6.88%α +5.76% · $98.51
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Director Saira Ramasastry filed a Form 144 notice of intent to sell 3,977 shares of Mirum Pharmaceuticals common stock, valued at approximately $397,700 based on the filing date. This is a modest sale relative to the company's $6.2B market cap and follows a pattern of regular monthly sales by the director (2,000 shares each in March, April, and May 2026). The filing is routine and does not signal material insider concern.
Key Facts
- Director Saira Ramasastry filed Form 144 to sell 3,977 shares of MIRM common stock.
- Estimated sale value is approximately $397,700 based on filing date.
- Ramasastry has sold 2,000 shares per month in March, April, and May 2026, suggesting a pre-planned trading pattern.
- The sale represents a tiny fraction of the company's $6.2B market cap.
- Recent insider activity shows only 1 sell totaling $219K in the past 30 days, consistent with routine diversification.
Financial Impact
~$397,700 sale by a director, immaterial relative to $6.2B market cap
Risk Factors
- No material risk identified from this filing alone.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001950047-26-005336 |
| Document: 0001950047-26-005336-index.html | 0001950047-26-005336 |
| Document: 0001950047-26-005336.txt | 0001950047-26-005336 |
Track record
27 reports on MIRM
5 of 5 bullish or bearish reports moved the stock their way by T+60. Best: +28.29% at T+20 after the Jun 11, 2026 report. 8 of 10 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $92.28 Now $91.58 −0.76% settles Feb 12
- Nov 13, 20263d ago Insider Cluster Neutral 3/10 Entry $93.54 Now $91.58 −2.10% settles Feb 12
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $93.33 Now $91.58 −1.88% settles Feb 10
- Nov 10, 20266d ago 8-K Bullish 6/10 Entry $94.42 Now $91.58 −3.01% settles Feb 8
- Nov 4, 202612d ago 144 Neutral 2/10 Entry $93.54 Now $91.58 −2.10% settles Feb 3
- Nov 4, 202612d ago 144 Neutral 2/10 Entry $93.54 Now $91.58 −2.10% settles Feb 3
- Nov 3, 202613d ago 8-K Bullish 6/10 Entry $96.97 Now $91.58 −5.56% settles Feb 2
- Oct 27, 202620d ago Institutional Cluster Mixed 4/10 Entry $85.81 Now $91.58 +6.72% settles Jan 26
- Oct 26, 202621d ago 8-K Bullish 6/10 Entry $85.56 Now $91.58 +7.04% settles Jan 25
- Oct 13, 20264w ago 8-K Bullish 7/10 Entry $79.62 Now $91.58 +15.02% settles Jan 8
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers